The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance

Schizophrenia Research

Volumn 103, Issue 1-3, 2008, Pages 94-103

  Lykkegaard, Kirsten ^a   Larsen, Philip J ^a   Vrang, Niels ^a   Bock, Camilla ^c   Bock, Troels ^b   Knudsen, Lotte Bjerre ^b  

^a Rheoscience A/S   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Atypical antipsychotics; Schizophrenia; Type 2 diabetes; Weight gain; Weight loss

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; FOOD INTAKE; GLUCOSE INTOLERANCE; IMPAIRED GLUCOSE TOLERANCE; MESENTERY; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RETROPERITONEAL FAT; SPRAGUE DAWLEY RAT; SUBCUTANEOUS FAT; TREATMENT OUTCOME; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY COMPOSITION; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INTRA-ABDOMINAL FAT; RATS; RATS, SPRAGUE-DAWLEY; SUBCUTANEOUS FAT, ABDOMINAL; WEIGHT GAIN;

EID: 48949115255     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.05.011     Document Type: Article

References (48)

1. 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
2. 2004 Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
3. Ader M., Kim S.P., Catalano K.J., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
4. Ahnaou A., Megens A.A., and Drinkenburg W.H. The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 48 (2003) 47-54
5. Albaugh V.L., Henry C.R., Bello N.T., et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14 (2006) 36-51
6. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
7. Ananth J., and Kolli S. Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?. Expert Opin. Drug Saf. 4 (2005) 55-68
8. Aravagiri M., Teper Y., and Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 20 (1999) 369-377
9. Baptista T., Rangel N., Fernandez V., et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr. Res. 93 (2007) 99-108
10. Beaudry G., Zekki H., Rouillard C., et al. Clozapine and dopamine D3 receptor antisense reduce cocaine- and amphetamine-regulated transcript expression in the rat nucleus accumbens shell. Synapse 51 (2004) 233-240
11. Biswasl P.N., Wilton L.V., Pearcel G.L., et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J. Psychopharmacol. 15 (2001) 265-271
12. Bonner-Weir S., Toschi E., Inada A., et al. The pancreatic ductal epithelium serves as a potential pool of progenitor cells. Pediatr. Diabetes 5 Suppl 2 (2004) 16-22
13. Bregenholt S., Moldrup A., Blume N., et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330 (2005) 577-584
14. Chang A.M., Jakobsen G., Sturis J., et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52 (2003) 1786-1791
15. Cooper G.D., Pickavance L.C., Wilding J.P., et al. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharmacol. (2006)
16. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004) 1187-1194
17. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
18. Feinglos M.N., Saad M.F., Pi-Sunyer F.X., et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet. Med. 22 (2005) 1016-1023
19. Fell M.J., Neill J.C., and Marshall K.M. Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. Eur. Neuropsychopharmacol. 14 (2004) 385-392
20. Gothelf D., Falk B., Singer P., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am. J. Psychiatry 159 (2002) 1055-1057
21. Goudie A.J., Cooper G.D., and Halford J.C. Antipsychotic-induced weight gain. Diabetes Obes. Metab. 7 (2005) 478-487
22. Graham K.A., Perkins D.O., Edwards L.J., et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychiatry 162 (2005) 118-123
23. Habener J.F. The incretin notion and its relevance to diabetes. Endocrinol. Metab. Clin. North Am. 22 (1993) 775-794
24. Hartfield A.W., Moore N.A., and Clifton P.G. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) 167 (2003) 115-122
25. Holst J.J. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol. Metab. 10 (1999) 229-235
26. Houseknecht K.L., Robertson A.S., Zavadoski W., et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32 (2007) 289-297
27. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
28. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30 (2007) 1487-1493
29. Kinon B.J., Kaiser C.J., Ahmed S., et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol. 25 (2005) 255-258
30. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43 (2000) 1664-1669
31. Kreymann B., Williams G., Ghatei M.A., et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
32. Larsen P.J., and Holst J.J. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul. Pept. 128 (2005) 97-107
33. Larsen P.J., Fledelius C., Knudsen L.B., et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50 (2001) 2530-2539
34. Larsen P.J., Vrang N., Tang-Christensen M., et al. Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides. Eur. J. Pharmacol. 440 (2002) 159-172
35. Little T.J., Pilichiewicz A.N., Russo A., et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J. Clin. Endocrinol. Metab. 91 (2006) 1916-1923
36. Mack C.M., Moore C.X., Jodka C.M., et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int. J. Obes. (Lond) 30 (2006) 1332-1340
37. Merchenthaler I., Lane M., and Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403 (1999) 261-280
38. Newcomer J.W., and Haupt D.W. The metabolic effects of antipsychotic medications. Can. J. Psychiatry 51 (2006) 480-491
39. Pouzet B., Mow T., Kreilgaard M., et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol. Biochem. Behav. 75 (2003) 133-140
40. Ratner R.E., Maggs D., Nielsen L.L., et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 8 (2006) 419-428
41. Raun K., von Voss P., Gotfredsen C.F., et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56 (2007) 8-15
42. Soreca I., Mauri M., Castrogiovanni S., et al. Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Bipolar Disord. 9 (2007) 784-788
43. St-Pierre L.S., and Persinger M.A. Extreme obesity in female rats following prepuberal induction of lithium-pilocarpine seizures and a single injection of acepromazine. Epilepsy Behav. 7 (2005) 411-418
44. Thakore J.H., Mann J.N., Vlahos I., et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 137-141
45. Thornton-Jones Z., Neill J.C., and Reynolds G.P. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J. Psychopharmacol. 16 (2002) 35-37
46. Tschoner A., Engl J., Laimer M., et al. Metabolic side effects of antipsychotic medication. Int. J. Clin. Pract. 61 (2007) 1356-1370
47. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007) 1608-1610
48. Zander M., Madsbad S., Madsen J.L., et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830